Search Results
Your search for early matches 10332 pages
Showing 1051 - 1100Study Finds Plant-Rich Foods, Nuts/Seeds May Benefit Childhood Cancer Survivors
A recent study, published by Wang et al in the Journal of Clinical Oncology, conducted as part of the St. Jude Lifetime Cohort (SJLIFE), may provide new insights into how diet may affect aging in adult survivors of childhood cancer. This study, involving 3,322 participants aged 18 to 65, found that ...
Unintentional Weight Loss May Be a Warning Sign of Cancer, Study Finds
Unintentional weight loss may be associated with an increased risk of receiving a cancer diagnosis within the next year, according to a recent study published by Wang et al in JAMA. Background Patients with advanced cancer often experience weight loss. However, weight loss is often not thought to...
Generic Drug Shortages and Essential Cancer Medicines
Decisions regarding the rationing of chemotherapy are commonplace in many countries around the world—including those where patients must pay for chemotherapy out of pocket—and increasingly so in cancer settings that treat both well-off and socioeconomically disadvantaged patients. However, these...
International Collaborative Research Efforts in Cardio-Oncology
At the 2023 Global Cardio-Oncology Symposium (GCOS), international experts explored the ongoing collaborative efforts to improve the cardiovascular health of patients being treated for cancer as well as the bidirectional challenges of translating basic research to clinical care. Focus on Basic and...
Expert Point of View: Laura Huppert, MD
Invited discussant Laura Huppert, MD, of the University of California, San Francisco, Comprehensive Cancer Center, focused her remarks on the need for biomarkers for selection of immunotherapy as part of neoadjuvant chemotherapy for hormone receptor–positive, HER2-negative breast cancer. “Hormone...
Neoadjuvant Chemoimmunotherapy Improves Pathologic Complete Response Rates in Subgroup Analysis of KEYNOTE-756
Pembrolizumab added to neoadjuvant chemotherapy followed by adjuvant pembrolizumab plus endocrine therapy improved pathologic complete responses in patients with early-stage, high-risk, estrogen receptor (ER)-positive, HER2-negative breast cancer, according to updated results of the phase III...
Expert Point of View: Heather Han, MD
Heather Han, MD, Research Director, Department of Breast Oncology, Moffitt Cancer Center, Tampa, commented on the latest update from the NATALEE trial: “Despite the established standard adjuvant therapy, many patients with hormone receptor–positive, early-stage breast cancer (including stages...
NATALEE Trial: Long-Term Results on Ribociclib Combination Therapy in Early-Stage Breast Cancer
Invasive disease–free survival continued to be significantly improved for patients with hormone receptor–positive, HER2-negative, early-stage breast cancer who received the CDK4/6 inhibitor ribociclib plus a nonsteroidal aromatase inhibitor compared with a nonsteroidal aromatase inhibitor alone....
Expert Point of View: Paul J. Hampel, MD
Paul J. Hampel, MD, a hematologist/oncologist at Mayo Clinic, Rochester, Minnesota, underscored the complexity of this arm of the adaptive FLAIR trial, which compared measurable residual disease (MRD)-directed ibrutinib plus venetoclax with standard, fixed-duration, FCR (fludarabine,...
Personalized Ibrutinib-Plus-Venetoclax Therapy: New Treatment Standard for Chronic Lymphocytic Leukemia?
A time-limited approach based on measurable residual disease (MRD) response could signal a potential paradigm shift for front-line treatment of chronic lymphocytic leukemia (CLL), according to data presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition1 and...
Expert Point of View: Ajay K. Nooka, MD, MPH, and Dan Vogl, MD, MSCE
Ajay K. Nooka, MD, MPH, Professor in the Department of Hematology and Medical Oncology at Emory University, and Dan Vogl, MD, MSCE, Associate Professor of Medicine at the Hospital of the University of Pennsylvania, shared their thoughts on the PERSEUS trial for The ASCO Post. Dr. Nooka noted that ...
Real-World Experience Mirrors PERSEUS Findings
At the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition, researchers from Emory University presented a real-world comparison of the largest cohort of patients with newly diagnosed multiple myeloma consecutively treated with either bortezomib, lenalidomide, and dexamethasone ...
PERSEUS: Daratumumab Regimen Significantly Improves Progression-Free Survival in Newly Diagnosed Multiple Myeloma
The addition of the CD38 monoclonal antibody daratumumab to a standard regimen for patients with newly diagnosed transplant-eligible multiple myeloma significantly prolonged progression-free survival vs standard treatment in the phase III PERSEUS trial. The study was reported as a late-breaking...
First-Line Nivolumab Plus Ipilimumab Shows Benefit in Metastatic Colorectal Cancer Subset
In the phase III CheckMate 8HW trial, previously untreated patients with microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) metastatic colorectal cancer derived significant benefit from an immunotherapy doublet of nivolumab plus ipilimumab in the first-line setting, which...
AUGMENT-101 Trial: Menin Inhibitor Revumenib Shows Activity in KMT2A-Rearranged Acute Leukemia
In heavily pretreated patients with a challenging type of acute leukemia, the menin inhibitor revumenib demonstrated clinically meaningful activity, including high rates of response and measurable residual disease (MRD) negativity, according to the efficacy and safety results of the phase II...
New Director of the University of Hawaii Cancer Center, Naoto T. Ueno, MD, PhD, FACP, Is Also a Two-Time Cancer Survivor
In this installment of The ASCO Post ’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Naoto T. Ueno, MD, PhD, FACP, Director of the University of Hawaii Cancer Center. Along with his duties leading the cancer center, Dr. Ueno leads translational breast cancer research...
Celebrating Excellence: Matthijs Oudkerk, PhD, MD, MSc, Honored for Contributions to Cancer Prevention and Research
The Prevent Cancer Foundation has honored Matthijs Oudkerk, PhD, MD, MSc, with the prestigious James L. Mulshine, MD, International Leadership Award. Dr. Oudkerk is Professor of Radiology at the University of Groningen and Chief Scientific Officer of the Institute for Diagnostic Accuracy in the...
Beyond Lung Cancer: Leveraging Machine Learning Techniques to Understand Other Diseases
Although computed tomography (CT) screening has emerged as an essential tool for the early detection of lung diseases, there is still a broad range of potential improvements to be made. According to recent research, understanding the patterns of onset for earlier prediction of disease may be...
Do Patients With Molecular MRD Detected After Colorectal Cancer Surgery Benefit From Adjuvant Chemotherapy?
Following surgery to remove a colorectal tumor, patients may have molecular measurable residual disease (MRD). Circulating tumor DNA (ctDNA), or liquid biopsy, may be used to detect molecular MRD in patients who underwent surgery for colorectal cancer and to determine whether they may benefit from...
Overall Survival and Long-Term Outcomes in the monarchE Trial
As reported in the Journal of Clinical Oncology by Priya Rastogi, MD, and colleagues, an interim analysis of overall survival in the phase III monarchE trial showed no significant benefit with the addition of 2 years of adjuvant abemaciclib to endocrine therapy in patients with hormone...
Normal Risk Ovarian Screening Study: Long-Term Update
As reported in the Journal of Clinical Oncology by Han et al, the 21-year update of the Normal Risk Ovarian Screening Study (NROSS) has shown that the NROSS screening strategy remains effective for the detection of ovarian cancer and detection at early disease stages. Study Details The NROSS...
Undocumented Cost-of-Care Discussions: A Missed Opportunity in Cancer Treatment
A recent study underscored the need for integrating cost-of-care conversations in cancer treatment. Results of the population-based analysis, presented at the 2023 ASCO Quality Care Symposium,1 showed that only about 25% of patients with newly diagnosed advanced non–small cell lung cancer (NSCLC)...
Medicaid Expansion May Improve Postsurgical Survival Outcomes in Patients With NSCLC
Investigators have found that Medicaid expansion under the Affordable Care Act may be associated with a reduced risk of early mortality following surgical resection in patients with non–small cell lung cancer (NSCLC), according to a recent study published by Nogueira et al in JAMA Network Open. The ...
Use of Lower-Than-Recommended Doses of Immune Checkpoint Inhibitors in Various Tumor Types: Indian Study
In an Indian single-institution study reported in JCO Global Oncology, Patel et al found that use of lower-than-recommended doses of immune checkpoint inhibitors showed activity across various tumor types. As stated by the investigators: “The cost of immune checkpoint inhibitors limits their...
MRD Status and Outcomes With Obinutuzumab- and Rituximab-Based Treatment in Follicular Lymphoma
In an analysis from the phase III GALLIUM study reported in the Journal of Clinical Oncology, Pott et al identified measurable residual disease (MRD) status and related outcomes among patients receiving obinutuzumab- and rituximab-based treatment for previously untreated follicular lymphoma. Study...
Study Identifies Potential Variations in U.S. Health Insurance Coverage at Cancer Diagnosis by State
Investigators have uncovered substantial state variations in health insurance coverage among U.S. patients newly diagnosed with cancer, according to a recent study published by Hu et al in Health Affairs Scholar. Background Over the past decade, health insurance coverage—which has been found to be...
Harinder Gill, MD, MBBS, on Acute Promyelocytic Leukemia: Assessing the Use of Oral Arsenic Trioxide, Retinoic Acid, and Ascorbic Acid
Harinder Gill, MD, MBBS, of The University of Hong Kong, discusses findings showing the use of an “AAA” regimen (pure oral arsenic trioxide combined with all-trans retinoic acid) in a risk-adapted strategy that minimized chemotherapy was highly effective and safe in patients with newly diagnosed...
Mazyar Shadman, MD, MPH, on Large B-Cell Lymphoma: Autologous Transplantation vs CAR T-Cell Therapy
Mazyar Shadman, MD, MPH, of the University of Washington, discusses new data suggesting that in patients with relapsed large B-cell lymphoma who achieve a complete response, treatment with autologous transplantation may be associated with a lower relapse rate and improved progression-free survival...
Reshma Jagsi, MD, DPhil, on Early-Stage Breast Cancer: 5-Year Outcomes With Endocrine Therapy and Breast-Conserving Surgery
Reshma Jagsi, MD, DPhil, of Emory University Winship Cancer Institute, discusses the IDEA trial of endocrine therapy without radiotherapy after breast-conserving surgery for postmenopausal patients between the ages of 50 and 69 with stage I breast cancer. The regimen demonstrated a low risk of...
Addition of Avasopasem to SBRT in Localized Pancreatic Cancer
Editor’s note: On publication of this news item reporting on a paper by Dr. Cullen Taniguchi and colleagues, The ASCO Post learned of Dr. Taniguchi’s untimely death on November 14, 2023. To read about the remarkable life and career of Dr. Taniguchi, please visit gsbs.uth.edu. In a phase Ib/II trial ...
A New Approach to Identifying Consumer Products That Contain Cancer-Causing Chemicals
Researchers may have uncovered a novel strategy to predict whether synthetic chemicals may cause breast cancer by examining their specific traits, according to a recent study published by Kay et al in Environmental Health Perspectives. Background The incidence of breast cancer—the most common...
ALL in Adults: Trial Updates and Clinical Considerations for Selecting Consolidation Therapy
Although pediatric patients with acute lymphoblastic leukemia (ALL) have seen a dramatic improvement in long-term survival rates over the past 40 years, from approximately 10% to over 95%, adults aged 29 and older have not experienced the same treatment benefits, with survival rates still below...
Long-Term Follow-up Supports Postneoadjuvant T-DM1 Over Trastuzumab in Early, High-Risk, HER2-Positive Breast Cancer
At a median follow-up of 8.4 years, adjuvant use of ado-trastuzumab emtansine (T-DM1) continued to improve invasive disease–free survival and overall survival compared with trastuzumab in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy. These ...
EGFR-Mutated Early-Stage NSCLC
This is Part 3 of New Directions in Nonmetastatic Non–Small Cell Lung Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Heather Wakelee, Tina Cascone, and Marina Garassino discuss the management of EGFR-mutated...
PD-L1–Negative Early-Stage NSCLC
This is Part 2 of New Directions in Nonmetastatic Non–Small Cell Lung Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Heather Wakelee, Tina Cascone, and Marina Garassino discuss the management of PD-L1–negative...
Use of Carvedilol to Help Prevent Heart Failure in Childhood Cancer Survivors
Researchers discovered that the blood vessel–relaxing agent carvedilol may be safe and effective at reducing the risk of heart failure in childhood cancer survivors, according to a recent study published by Armenian et al in The Lancet Oncology. These findings indicate carvedilol may improve...
Novel Vaccine May Delay Relapse in KRAS-Mutated Pancreatic and Colorectal Cancers
A novel vaccine may be effective at preventing relapse in patients with KRAS-mutated pancreatic and colorectal cancers, according to a recent study published by Pant et al in Nature Medicine. Background KRAS-mutated cancers make up about 25% of all solid tumors, including 90% of pancreatic cancer...
Adam S. Kittai, MD, on Richter’s Transformation: Anti-CD19 CAR T-Cell Therapy
Adam S. Kittai, MD, of The Ohio State University, discusses his data supporting the use of CAR T-cell therapy for patients with Richter’s transformation. Given the high response rate to CD19 CAR T-cell treatment, along with early relapse in most patients, allogeneic stem cell transplantation at...
Long-Term Results With Front-Line Dasatinib/Blinatumomab for Philadelphia Chromosome–Positive ALL
As reported in the Journal of Clinical Oncology by Foà et al, long-term results of the Italian D-ALBA study have shown that a chemotherapy-free induction/consolidation regimen of dasatinib followed by blinatumomab maintained highly favorable outcomes in the front-line treatment of adult patients...
Peter Schmid, MD, PhD, on Early-Stage TNBC: Updated Survival Results From KEYNOTE-522
Peter Schmid, MD, PhD, of Queen Mary University of London and Barts Cancer Institute, discusses phase III findings from KEYNOTE-522 showing that neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab continues to show a clinically meaningful improvement in event-free...
Cynthia X. Ma, MD, PhD, on Metastatic Breast Cancer: Early Results on Copanlisib, Fulvestrant, and Abemaciclib
Cynthia X. Ma, MD, PhD, of Washington University School of Medicine in St. Louis, discusses phase I findings showing the safety and tolerability of copanlisib and fulvestrant in combination with continuous or intermittent abemaciclib in patients with estrogen receptor–positive, HER2-negative...
Expert Point of View: Elizabeth Smyth, MD
Invited discussant of the phase I trial of the claudin 18.2-specific antibody-drug conjugate CMG901 in advanced gastric or gastroesophageal junction cancer was Elizabeth Smyth, MD, of Oxford University Hospitals NHS Foundation Trust. She said CMG901 demonstrated “encouraging results,” but more...
ASCO and Ontario Health Publish New Recommendations for Systemic Therapy in SCLC
A newly published guideline update from ASCO and Ontario Health provides evidence-based recommendations on the use of systemic therapy for small cell lung cancer (SCLC).1 Recommendations cover where novel agents fit in the treatment landscape, the management of disease in older patients with...
International Collaborative Research Efforts in Cardio-oncology: Focus on Basic and Translational Science
Translational research is a key ingredient in guiding both genetic and pharmacologic cardioprotective approaches in patients being treated for cancer, according to international experts from the International Cardio-Oncology Society and the Global Cardio-Oncology Symposium (GCOS) committee. Fadi N. ...
Early Detection and Management in Merkel Cell Carcinoma
This is Part 3 of Evolving Skin Cancer Management, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Pauline Funchain, Alison Vidimos, and Lisa Zaba discuss the importance of early detection and multidisciplinary treatment of...
Community Program Cuts Treatment Delays in Half for Minority and Low-Income Patients
A program aimed at improving access to high-quality cancer care has significantly increased adherence to cancer treatment among minority and low-income communities, according to data presented at the 2023 ASCO Quality Care Symposium.1 The introduction of the ALCANCE-PLUS program in Monterey County, ...
All Adult Oncologists Are Geriatric Oncologists
The data developed over the past few years have overwhelmingly favored geriatric assessment as part of the routine care for older patients with cancer. It has become the standard of care. ASCO has recently published a Practical Geriatric Assessment to aid in the implementation of this vital...
Cardiovascular Health of Women Treated for Cancer: Understanding the Long-Term Risks
At the 2023 Global Cardio-Oncology Summit in Madrid, in a joint session with ASCO and the International Cardio-Oncology Society, Anita Arnold, DO, FACC, MBA, Director, Noninvasive Cardiology, and Director of Cardio-Oncology, Lee Memorial Health Systems, Fort Myers, Florida, discussed the...
Lung Nodule Program May Help Detect Cancer in Patients Age-Ineligible for Lung Cancer Screening
Researchers have found that adopting a Lung Nodule Program may increase early lung cancer detection in patients who are not eligible for lung cancer screening under existing age-eligibility criteria, according to a recent study published by Liao et al in the Journal of Thoracic Oncology. ...
HPV ctDNA Detection After Chemoradiation in Patients With Cervical Cancer
In a study reported in the Journal of Clinical Oncology, Han et al found that persistent human papillomavirus (HPV) circulating tumor DNA (ctDNA) after chemoradiation was associated with poorer outcomes in patients with cervical cancer. Patients at high risk of poorer outcomes could also be...
